Diabetic cardiomyopathy: mechanisms, diagnosis and treatment

被引:267
作者
Hayat, SA
Patel, B
Khattar, RS
Malik, RA
机构
[1] Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England
[2] Northwick Pk Hosp & Clin Res Ctr, Dept Cardiol, Harrow HA1 3UJ, Middx, England
[3] Manchester Royal Infirm, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England
关键词
diabetic cardiomyopathy; diagnosis; echocardiography; molecular mechanism; treatment;
D O I
10.1042/CS20040057
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Independent of the severity of coronary artery disease, diabetic patients have an increased risk of developing heart failure. This clinical entity has been considered to be a distinct disease process referred to as 'diabetic card iomyopathy'. Experimental studies suggest that extensive metabolic perturbations may underlie both functional and structural alterations of the diabetic myocardium. Translational studies are, however, limited and only partly explain why diabetic patients are at increased risk of cardiomyopathy and heart failure. Although a range of diagnostic methods may help to characterize alterations in cardiac function in general, none are specific for the alterations in diabetes. Treatment paradigms are very much limited to interpretation and translation from the results of interventions in non-diabetic patients with heart failure. This suggests that there is an urgent need to conduct pathogenetic, diagnostic and therapeutic studies specifically in diabetic patients with cardiomyopathy to better understand the factors which initiate and progress diabetic cardiomyopathy and to develop more effective treatments.
引用
收藏
页码:539 / 557
页数:19
相关论文
共 196 条
[1]  
Adler AI, 1999, AM HEART J, V138, pS353
[2]   BENEFICIAL-EFFECTS OF VERAPAMIL IN DIABETIC CARDIOMYOPATHY [J].
AFZAL, N ;
GANGULY, PK ;
DHALLA, KS ;
PIERCE, GN ;
SINGAL, PK ;
DHALLA, NS .
DIABETES, 1988, 37 (07) :936-942
[3]   Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: Effects of transforming growth factor beta(1), thyroid hormone, angiotensin II and basic fibroblast growth factor [J].
Agocha, A ;
Lee, HW ;
EghbaliWebb, M .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (08) :2233-2244
[4]   PRECLINICAL ABNORMALITY OF LEFT-VENTRICULAR FUNCTION IN DIABETES-MELLITUS [J].
AHMED, SS ;
JAFERI, GA ;
NARANG, RM ;
REGAN, TJ .
AMERICAN HEART JOURNAL, 1975, 89 (02) :153-158
[5]   AUGMENTATION OF ATRIAL CONTRIBUTION TO LEFT-VENTRICULAR FILLING IN IDDM SUBJECTS AS ASSESSED BY DOPPLER ECHOCARDIOGRAPHY [J].
AIRAKSINEN, KEJ ;
KOISTINEN, MJ ;
IKAHEIMO, MJ ;
HUIKURI, HV ;
KORHONEN, U ;
PIRTTIAHO, H ;
LINNALUOTO, MK ;
TAKKUNEN, JT .
DIABETES CARE, 1989, 12 (02) :159-161
[6]  
*AM ASS DIAB CAR, 1993, ROL CARD RISK FACT P, V16, P72
[7]   Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus [J].
Annonu, AKMH ;
Fattah, AA ;
Mokhtar, S ;
Ghareeb, S ;
Elhendy, A .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2001, 14 (09) :885-891
[8]  
[Anonymous], 1970, Diabetes, V19, P747
[9]   Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study [J].
Arnold, JMO ;
Yusuf, S ;
Young, J ;
Mathew, J ;
Johnstone, D ;
Avezum, A ;
Lonn, E ;
Pogue, J ;
Bosch, J .
CIRCULATION, 2003, 107 (09) :1284-1290
[10]   An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness [J].
Asif, M ;
Egan, J ;
Vasan, S ;
Jyothirmayi, GN ;
Masurekar, MR ;
Lopez, S ;
Williams, C ;
Torres, RL ;
Wagle, D ;
Ulrich, P ;
Cerami, A ;
Brines, M ;
Regan, TJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2809-2813